TRIM17

Across TCGA pan-cancer cohorts, TRIM17 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of TRIM17’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where TRIM17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRIM17 is over-expressed in tumor, although a few such as KICH and KIRC show the opposite, repressed pattern.

BLCA, LIHC, and KICH are the cancer types where TRIM17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRIM17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+1.403	<.001	8	view →
LIHC	All	II,III,IV	+0.647	<.001	8	view →
KICH	Male	All	−0.540	<.001	8	view →
KIRC	Male	III,IV	−0.318	<.001	8	view →
THCA	All	All	+0.413	<.001	7	view →
CHOL	Female	All	+2.666	<.001	5	view →
LUSC	Male	All	+0.891	<.001	5	view →
UCEC	All	All	+1.106	.005	4	view →
LUAD	All	All	+0.623	<.001	4	view →
STAD	All	All	+0.445	.010	4	view →
COAD	All	All	+0.171	.004	3	view →
PRAD	All	All	−0.287	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

TRIM17–BLCA

Open the BLCA breakdown →